6/28/23, 12:03 AM ADVANCE (intensive glucose control) Pathway Feedback Search Clinical Topics Home Studies ADVANCE (intensive glucose control) ADVANCE (intensive glucose control) Disease Diabetes mellitus type 2 Trial question What is the role of intensive glucose control in patients with T2DM? Study design Multi-center Double blinded RCT Population Characteristics of study participants 42.0% female N = 11140 58.0% male 11140 patients (4733 female, 6407 male) Inclusion criteria: patients with T2DM Key exclusion criteria: a definite indication for, or contraindication to, any of the study treatments or a definite indication for long-term insulin therapy at the time of study entry Interventions N=5571 intensive glucose control (using gliclazide, modified release 30-120 mg daily, and other drugs, targeting glycated Hgb value 6.5%) N=5569 standard glucose control (target glycated Hgb levels defined on the basis of local guidelines) Primary outcome https://web.pathway.md/studies/recJlr36CpnHtHVHC 1/2 6/28/23, 12:03 AM ADVANCE (intensive glucose control) Pathway Macrovascular and microvascular events 20.0 % 20 18.1 15.0 % 10.0 % Significant decrease 5.0 % NNT = 53 0.0 % Intensive glucose control Standard glucose control Significant decrease in macrovascular and microvascular events (18.1% vs. 20%; HR 0.9, 95% CI 0.82 to 0.98) Secondary outcomes Significant decrease in major microvascular events (9.4% vs. 10.9%; HR 0.86, 95% CI 0.77 to 0.97) Significant decrease in nephropathy (4.1% vs. 5.2%; HR 0.79, 95% CI 0.66 to 0.93) No significant difference in death from any cause (8.9% vs. 9.6%; HR 0.93, 95% CI 0.83 to 1.06) Safety outcomes No significant difference in RRT or death from renal causes. Significant difference in severe hypoglycemia (2.7% vs. 1.5%). Conclusion In patients with T2DM, intensive glucose control was superior to standard glucose control with respect to macrovascular and microvascular events. Reference ADVANCE Collaborative Group, Patel A, MacMahon S et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med. 2008 Jun 12;358(24):2560-72. Open reference URL https://web.pathway.md/studies/recJlr36CpnHtHVHC 2/2